RecruitingNCT06820723
Brain effects of one CYB003 dose in depression with anxiety
About this title
Read the official source — NCT06820723Medication studyAges 21–65United States
Understand this study
Who could participate?
Listed age limits: 21 years to 65 years.
What will I do during this study?
You receive one dose of CYB003 or placebo (an inactive comparison treatment), with psychological support before, during and after administration. Assessments at baseline and on Days 2 and 21 include interviews, questionnaires, thinking tests, brain imaging, EEG (recording of the brain’s electrical activity)-related recordings and blood sampling.
- Listed locations
- ColumbusSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: November 1, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Ohio State University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT06820723
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Columbus
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Ohio State University, a university.
Does this study involve medication?
Yes. The study involves medication, including CYB003 and Placebo.
Who can participate?
Listed age limits: 21 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
